Department of Medicine, University of Hong Kong, Hong Kong, China.
Cancer. 2009 Dec 1;115(23):5441-9. doi: 10.1002/cncr.24609.
This study aimed to determine the potential diagnostic value of migration-inhibitory factor (MIF) for gastric cancer in patients presenting with dyspepsia and its prognostic value for gastric cancer.
A cohort of 97 patients with histologically confirmed gastric adenocarcinoma and 222 patients with dyspepsia were recruited. Enzyme-linked immunosorbent assay was used to measure serum MIF and carcinoembryonic antigen (CEA).
The serum MIF concentrations were 6554.0 +/- 204.1 pg/mL and 1453.7 +/- 79.9 pg/mL, respectively, in gastric cancer patients and dyspeptic patients (P < .001). Serum MIF levels increased with the advancing gastric pathologies (P < .001). With the cutoff value of 3230 pg/mL, serum MIF had sensitivity, specificity, and accuracy of 83.5%, 92.3%, and 89.7%, respectively, in diagnosing gastric cancer, whereas the rates were 60.8%, 83.3%, and 76.5%, respectively, for serum CEA. Gastric cancer patients with serum MIF levels above 6600 pg/mL had a lower 5-year survival rate than those with serum MIF level below that level (P = .012). Higher serum CEA levels were also associated with poor survival. The prediction for 5-year survival was even better (P = .0001), using a combination of serum MIF and CEA.
Serum MIF level, which correlates with gastric MIF expression, is a better molecular marker than CEA in diagnosing gastric cancer in patients presenting with dyspepsia. A combination of serum MIF and CEA predicts 5-year survival better than the individual test.
本研究旨在确定迁移抑制因子（MIF）在消化不良患者中对胃癌的潜在诊断价值及其对胃癌的预后价值。
招募了一组 97 例经组织学证实的胃腺癌患者和 222 例消化不良患者。采用酶联免疫吸附试验测定血清 MIF 和癌胚抗原（CEA）。
胃癌患者血清 MIF 浓度为 6554.0±204.1 pg/mL，消化不良患者为 1453.7±79.9 pg/mL（P<.001）。血清 MIF 水平随胃病变进展而升高（P<.001）。以 3230 pg/mL 为截断值，血清 MIF 诊断胃癌的敏感性、特异性和准确性分别为 83.5%、92.3%和 89.7%，而血清 CEA 分别为 60.8%、83.3%和 76.5%。血清 MIF 水平高于 6600 pg/mL 的胃癌患者 5 年生存率低于血清 MIF 水平低于该水平的患者（P=.012）。较高的血清 CEA 水平也与不良预后相关。使用血清 MIF 和 CEA 的组合，对 5 年生存率的预测甚至更好（P=.0001）。
与胃 MIF 表达相关的血清 MIF 水平是消化不良患者诊断胃癌的比 CEA 更好的分子标志物。血清 MIF 和 CEA 的组合比单独测试预测 5 年生存率更好。
